Novartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to 400 million euros ($434 million).
Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican
